Litcius/Paper detail

521MO Efficacy of pembrolizumab monotherapy (PM) for advanced clear cell gynaecological cancer (CCGC): Phase II PEACOCC trial

Rebecca Kristeleit, Andrew R. Clamp, C. Gourley, René L. Roux, Marcia Hall, M-J. Devlin, Rachel Nirsimloo, Valentinos Kounnis, Lucy Hughes, Nicholas Counsell, Laura Farrelly, Robert F. Miller

2022Annals of Oncology31 citationsDOI

Topics & Concepts

MedicineInternal medicineClinical endpointPembrolizumabAdverse effectProgression-free survivalGastroenterologyPhases of clinical researchOncologyChemotherapyClinical trialSurgeryCancerImmunotherapyOvarian cancer diagnosis and treatmentLymphoma Diagnosis and TreatmentEndometrial and Cervical Cancer Treatments
521MO Efficacy of pembrolizumab monotherapy (PM) for advanced clear cell gynaecological cancer (CCGC): Phase II PEACOCC trial | Litcius